These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8601556)

  • 41. The first Japanese pediatric case of obsessive-compulsive disorder who responded to a selective serotonin re-uptake inhibitor.
    Furusho J; Kubagawa T; Saitoh N; Matsuzaki K; Yamakawa H; Iikura Y
    Pediatr Int; 2000 Aug; 42(4):451-2. PubMed ID: 10986886
    [No Abstract]   [Full Text] [Related]  

  • 42. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
    Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
    J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined SSRI-RIMA treatment in refractory depression. Safety data and efficacy.
    Ebert D; Albert R; May A; Stosiek I; Kaschka W
    Psychopharmacology (Berl); 1995 Jun; 119(3):342-4. PubMed ID: 7675971
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trichotilliomania responding to low-dose fluvoxamine.
    Ikenouchi-Sugita A; Yoshimura R; Ueda N; Nakamura J
    Psychiatry Clin Neurosci; 2009 Oct; 63(5):701-2. PubMed ID: 19788633
    [No Abstract]   [Full Text] [Related]  

  • 45. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity.
    Cusin C; Serretti A; Zanardi R; Lattuada E; Rossini D; Lilli R; Lorenzi C; Smeraldi E
    Int J Neuropsychopharmacol; 2002 Mar; 5(1):27-35. PubMed ID: 12057029
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients.
    Lu ML; Lane HY; Chen KP; Jann MW; Su MH; Chang WH
    J Clin Psychiatry; 2000 Aug; 61(8):594-9. PubMed ID: 10982203
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-dose sildenafil citrate for selective serotonin reuptake inhibitor-associated ejaculatory delay: open clinical trial.
    Seidman SN; Pesce VC; Roose SP
    J Clin Psychiatry; 2003 Jun; 64(6):721-5. PubMed ID: 12823089
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Late onset OCD.
    Bhattacharyya S; Khanna S
    Aust N Z J Psychiatry; 2004 Jun; 38(6):477-8. PubMed ID: 15209842
    [No Abstract]   [Full Text] [Related]  

  • 49. The onset and time course of response of negative symptoms to add-on fluvoxamine treatment.
    Silver H; Nassar A; Aharon N; Kaplan A
    Int Clin Psychopharmacol; 2003 Mar; 18(2):87-92. PubMed ID: 12598819
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series.
    Stoll AL; Pillay SS; Diamond L; Workum SB; Cole JO
    J Clin Psychiatry; 1996 Feb; 57(2):72-6. PubMed ID: 8591972
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Controlled withdrawal of selective serotonin reuptake inhibitor drugs in elderly patients in nursing homes with no indication of depression.
    Ulfvarson J; Adami J; Wredling R; Kjellman B; Reilly M; von Bahr C
    Eur J Clin Pharmacol; 2003 Dec; 59(10):735-40. PubMed ID: 14595527
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
    Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T
    Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression.
    Fischer P; Tauscher J; Küfferle B; Kasper S
    Int Clin Psychopharmacol; 1998 Mar; 13(2):83-6. PubMed ID: 9669189
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
    Burke WJ; Gergel I; Bose A
    J Clin Psychiatry; 2002 Apr; 63(4):331-6. PubMed ID: 12000207
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SSRI-induced parkinsonism may be an early sign of future Parkinson's disease.
    Gönül AS; Aksu M
    J Clin Psychiatry; 1999 Jun; 60(6):410. PubMed ID: 10401924
    [No Abstract]   [Full Text] [Related]  

  • 56. A case of pervasive developmental disorder complicated by social anxiety disorder responding well to fluvoxamine therapy.
    Yano H; Matsumoto H
    Tokai J Exp Clin Med; 2011 Jul; 36(2):44-6. PubMed ID: 21769772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fluvoxamine. A review of its safety profile in world-wide studies.
    Wagner W; Zaborny BA; Gray TE
    Int Clin Psychopharmacol; 1994; 9(4):223-7. PubMed ID: 7868844
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Onset of clinical effects and plasma concentration of fluvoxamine in Japanese patients.
    Katoh Y; Uchida S; Kawai M; Takei N; Mori N; Kawakami J; Kagawa Y; Yamada S; Namiki N; Hashimoto H
    Biol Pharm Bull; 2010; 33(12):1999-2002. PubMed ID: 21139240
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo.
    Mallick R; Chen J; Entsuah AR; Schatzberg AF
    J Clin Psychiatry; 2003 Mar; 64(3):321-30. PubMed ID: 12716275
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients.
    Fabre L; Birkhimer LJ; Zaborny BA; Wong LF; Kapik BM
    Int Clin Psychopharmacol; 1996 Jun; 11(2):119-27. PubMed ID: 8803649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.